EASD: Boehringer Ingelheim, Lilly’s Jardiance holds CV benefit regardless of blood sugar starting point

LISBON, Portugal—Back in 2015, Boehringer Ingelheim and Eli Lilly were the first drugmakers to show that a diabetes med could cut the risk of cardiovascular death, and they’re still workin…
Read the full story: FiercePharma: Pharma